The story of Viagra presents a nuanced case for observers in the porn medicinal sector. While initially a phenomenal success, creating huge profits, the exclusivity lapse and the subsequent flood of off-brand alternatives have significantly affected earnings. This poses questions about the ongoing sustainability of similar medication developments a